[ME14] Meet the Experts 14　Neoadjuvant therapy with durvalumab and tremelimumab for patients with high-risk localized bladder cancer ineligible for cisplatin-based chemotherapy

[ME14] Neoadjuvant therapy with durvalumab and tremelimumab for patients with high-risk localized bladder cance ineligible for cisplatin-based chemotherapy

^○Jianjun Gao (Department of Genitourinary Medical Oncology)